Psychiatric News
Journal Home Search Current Issue Past Issues Subscribe All APPI Journals Help Contact Us
 
Quicksearch
Advanced Search
Or Search All APPI Journals
Services
* Email this article to a Colleague
* Similar articles in this journal
* Alert me to new issues of the journal
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via Google Scholar
Google Scholar
* Articles by Bender, E.
* Search for Related Content
Psychiatric News January 3, 2003
Volume 38 Number 1
© 2003 American Psychiatric Association
p. 4


Government News

Federal Office Gives Psychiatrist Key Addiction-Research Post

Eve Bender

The White House Office of National Drug Control Policy is funding cutting-edge gene and protein analysis technology to search for the molecular causes of addiction.

The White House Office of National Drug Control Policy (ONDCP) Counterdrug Technology Assessment Center (CTAC) has chosen an APA member as one of the recipients of a $5.85 million grant to investigate the genetic factors that predispose people to addiction.

Patricia Ordorica, M.D., is associate chief of staff for mental health and behavioral sciences at the James A. Haley VA Hospital in Tampa and clinical director of the CTAC Drug Addiction Study. She is also the director of addictive disorders and associate professor of psychiatry at the University of South Florida in Tampa.

In APA, Ordorica is chair of the APA/CMHS Minority Fellowship Selection and Advisory Committee, vice chair of APA’s Scientific Program Committee, and a member of the Vestermark Award Corresponding Committee.

As clinical director of the study, Patricia Ordorica, M.D., will oversee all administrative and clinical aspects of the drug addiction treatment research, and with principal investigator Michael Mullan, M.D., Ph.D., supervise the research components and operations. Mullan is director of the Roskamp Institute, a research facility in Tampa.

Patients with substance use disorders will be recruited from the veterans hospital and other CTAC-funded research centers in a sample that will top 1,000 patients. The research team will use the ONDCP funding to purchase the latest gene chip and protein analysis technology, which will enable them to study hundreds of thousands of human genes and the proteins expressed by those genes.

By identifying the genes and proteins activated by different drugs of abuse, the researchers hope to design a therapeutic intervention that will ultimately disrupt the addiction process. {blacksquare}





Services
* Email this article to a Colleague
* Similar articles in this journal
* Alert me to new issues of the journal
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via Google Scholar
Google Scholar
* Articles by Bender, E.
* Search for Related Content


Get information about faster international access.

Privacy Policy

Copyright © 2003 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us

American Psychiatric Publishing, Inc. American Psychiatric Association
1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901 * 800-368-5777 * appi at psych.org